Development of submodels of organs within physiologically-based pharmacokinetic (PBPK)
principles and beyond simple perfusion limitations may be challenging because of …

Accepted: 6 October 2021© The Author (s), under exclusive licence to Springer Science+
Business Media, LLC, part of Springer Nature 2021corrected publication 2021 embedded in …

A prerequisite for the prediction of the magnitude of P-glycoprotein (P-gp)-mediated drug–
drug interactions between digoxin and P-gp inhibitors (eg verapamil and its metabolite …

It has been previously demonstrated that IC50 values for inhibition of digoxin transport
across confluent polarized cell monolayers are system-dependent. Digoxin IC50 data from …

To determine the contribution of the mdr1a gene product to digoxin pharmacokinetics, we
constructed a physiologically based pharmacokinetic model for digoxin in mdr1a (−/−) and …

Digoxin is the recommended substrate for assessment of P-glycoprotein (P-gp)-mediated
drug–drug interactions (DDIs) in vivo. The overall aim of our study was to investigate the …

The conventional approach to approximating the pharmacokinetics of drugs in patients with
chronic kidney disease (CKD) only accounts for changes in the estimated glomerular …

Background Digoxin is a cardiac glycoside that was introduced to cardiovascular medicine
more than 200 years ago. Its use is associated with large variability, which complicates …

The programme for the 2015 AAPS Annual Meeting and Exhibition (Orlando, FL; 25–29
October 2015) included a sunrise session presenting an overview of the state-of-the-art tools …

Digoxin is a drug that is commonly used to treat congestive heart failure. Because of
digoxin's narrow therapeutic index, patients are susceptible to drug-drug interaction …